PAVmed (PAVM) Upgraded to Buy: Here's What You Should Know

Core Viewpoint - PAVmed Inc. has been upgraded to a Zacks Rank 2 (Buy), indicating a positive trend in earnings estimates which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Price Movement - The Zacks rating system is based on changes in earnings estimates, which are strongly correlated with near-term stock price movements [4][6]. - Rising earnings estimates for PAVmed suggest an improvement in the company's underlying business, likely leading to increased stock prices [5][10]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with a strong historical performance, particularly for Zacks Rank 1 stocks which have averaged a +25% annual return since 1988 [7][9]. - PAVmed's upgrade to Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, indicating a strong potential for market-beating returns in the near term [10]. Earnings Estimate Revisions for PAVmed - For the fiscal year ending December 2025, PAVmed is expected to earn -$1.14 per share, reflecting a 50.9% change from the previous year [8]. - Over the past three months, the Zacks Consensus Estimate for PAVmed has increased by 48.5%, indicating a positive shift in analyst sentiment [8].